% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tomsitz:277719,
      author       = {D. Tomsitz and T. Ruf and M. Heppt and R. Staeger and E.
                      Ramelyte and R. Dummer and M. Garzarolli and F. Meier and E.
                      Meier and H. Richly and T. Gromke and J. Siveke$^*$ and C.
                      Franklin and K.-C. Klespe and C. Mauch and T. Kilian and M.
                      Seegräber and B. Schilling and L. E. French and C. Berking
                      and L. Heinzerling},
      title        = {{T}ebentafusp in {P}atients with {M}etastatic {U}veal
                      {M}elanoma: {A} {R}eal-{L}ife {R}etrospective {M}ulticenter
                      {S}tudy},
      journal      = {Cancers},
      volume       = {15},
      number       = {13},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01436},
      pages        = {3430},
      year         = {2023},
      abstract     = {Background: Tebentafusp has recently been approved for the
                      treatment of metastatic uveal melanoma (mUM) after proving
                      to have survival benefits in a first-line setting.Patients
                      and methods: This retrospective, multicenter study analyzed
                      the outcomes and safety of tebentafusp therapy in 78
                      patients with mUM.Results: Patients treated with tebentafusp
                      had a median PFS of 3 months $(95\%$ CI 2.7 to 3.3) and a
                      median OS of 22 months $(95\%$ CI 10.6 to 33.4). In contrast
                      to a published Phase 3 study, our cohort had a higher rate
                      of patients with elevated LDH $(65.4\%$ vs. $35.7\%)$ and
                      included patients with prior systemic and local ablative
                      therapies. In patients treated with tebentafusp following
                      ICI, there was a trend for a longer median OS (28 months,
                      $95\%$ CI 26.9 to 29.1) compared to the inverse treatment
                      sequence (24 months, $95\%$ CI 13.0 to 35.0, p = 0.257). The
                      most common treatment-related adverse events were cytokine
                      release syndrome in $71.2\%$ and skin toxicity in $53.8\%$
                      of patients. Tumor lysis syndrome occurred in one
                      patient.Conclusions: Data from this real-life cohort showed
                      a median PFS/OS similar to published Phase 3 trial data.
                      Treatment with ICI followed by tebentafusp may result in
                      longer PFS/OS compared to the inverse treatment sequence.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37444540},
      doi          = {10.3390/cancers15133430},
      url          = {https://inrepo02.dkfz.de/record/277719},
}